Novasep Appoints CEO Michel Spagnol as Chairman
News Mar 05, 2014
Novasep has announced the appointment of Michel Spagnol as chairman of the Supervisory Board, following the departure of Roger-Marc Nicoud, the founder of the group. Novasep also provides an update of its strategic projects.
Michel Spagnol joined Novasep as its CEO in June 2013. Since then, he has reinforced the executive management team with the appointments of Christian Thiry as chief financial officer, Thierry Van Nieuwenhove as president of the Synthesis Business Unit and the promotion of Nadege Laborde as president of the Industrial Biotech Unit.
Michel Spagnol also engaged the company in a number of strategic orientations, encompassing commercial, operational, human and innovation excellence, aimed at focusing on customer satisfaction.
Novasep has achieved significant milestones for its key development projects, such as the completion of the world’s largest chromatographic plant for the purification of omega-3s at its Mourenx facility, France, and the successful validation of its ADC payload commercial production workshops at its Le Mans facility, France.
In the last nine months, these facilities and the Leverkusen site in Germany received successful FDA inspections, demonstrating Novasep’s continued commitment to quality.
“Since October 2012, as chairman of Novasep’s Supervisory Board, I have assisted the executive management team in order to ensure that my succession proceeds in the best possible conditions,” said Roger-Marc Nicoud. “Novasep achieved satisfying growth in 2013. The company has promising projects underway and the necessary human and financial resources to achieve them. With the arrival of Michel Spagnol as CEO, I consider my support work to be completed. I have decided to devote myself entirely to other technical and scientific activities. I wish Michel all the best in his new role of CEO and chairman of the Supervisory Board and great success to all Novasep employees.”
“I thank Roger Marc for his never-ending enthusiasm and contribution to the group’s development and I have profound respect for what he has achieved,” said Michel Spagnol, CEO and chairman of the Supervisory Board. “A unique entrepreneur, he succeeded in building from scratch a global leader in the life science manufacturing industry, recognized worldwide for its unique technologies and capabilities. Novasep is evolving, with a strong leadership team and a new logo ‘Passion and smart processes’, representing our refocused strategy. We will continue building on our strong foundations while developing on the excellence of our services and technologies. I wish Roger-Marc continued success in his new endeavors.”
“We would like to thank Roger-Marc who, over the last year and a half, has contributed his unprecedented experience and scientific expertise as chairman of Novasep’s Supervisory Board. We wish him all the best for his new endeavors,” said Jean-Yves Gilet, director - Bpifrance ETI/GE.
Gilet continued, “We are confident about Novasep’s recent developments. The company is implementing promising projects such as the ADC payload production capacities in the Le Mans facility and the chromatographic plant for the purification of omega-3s in Mourenx. We fully support its strong management team led by Michel Spagnol who we are happy to see appointed as chairman of the Supervisory Board.”
Fossilized Algae Hold Promise for Improved Food Safety TestingNews
Researchers, exploiting thin-layer chromatography and surface-enhanced Raman scattering, have used fossilized remains of algae to take a key step toward being able to more sensitively detect harmful contaminants in food.READ MORE
Rapid Removal of Arsenic From Drinking Water...By Moss!News
A moss capable of removing arsenic from contaminated water has been discovered by researchers. And it happens quickly – in just one hour, the arsenic level is so low that the water is no longer harmful for people to drink.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018